As previously reported, Raymond James analyst Dane Leone upgraded Regeneron to Market Perform from Underperform, arguing that there are "limited" remaining clinical downside catalysts during 2023. However, the firm said it expects continued debate around the outlook for Eylea, Vabysmo and 8mg aflibercept t weigh on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints
- Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
- Regeneron announces FDA approval of Evkeeza for young children
- Regeneron, Sanofi announce EC approval of Dupixent
- Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis